To the Market

The European Commission has given its seal of approval to the continent’s first gene therapy — a treatment for a lipid-processing disorder — which will be sold in Europe beginning in late 2013, The Scientist reports.

According to the article, the EC has approved the use of Glybera, a therapy that “utilizes viral vectors to deliver DNA encoding a lipid-processing enzyme to patients lacking a functional copy due to a gene mutation.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.